烧伤中心患者黏菌素治疗结局分析
按理想体重每日总剂量>5mg/kg与临床失败显著减少相关(OR=0.21;95%CI 0.05, 0.91),且未观察到肾毒性增加。
要点
- 按IBW每日总剂量>5mg/kg与临床失败减少独立相关。
- 以创面为主要感染源、肌酐清除率91-120mL/min及接受肾脏替代治疗者临床失败显著更高。
- 较高剂量组与较低剂量组肾毒性无差异。
核心结论
- 在烧伤中心接受静脉CMS的患者中,按IBW每日总剂量>5mg/kg者临床成功率显著更高,且该剂量范围内未见肾毒性增加。
主要发现
- 每日总剂量>5mg/kg IBW与临床失败显著减少相关(OR=0.21;95%CI 0.05, 0.91)。
- 以创面为主要感染源、肌酐清除率91-120mL/min及接受肾脏替代治疗的患者临床失败显著更高。
- 每日总剂量>5mg/kg IBW与≤5mg/kg IBW两组间肾毒性无差异。
临床怎么用
- 对烧伤中心需静脉CMS治疗的多重耐药革兰阴性菌感染患者,可考虑按IBW每日总剂量>5mg/kg给药以改善临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Intravenous colistimethate sodium (CMS) use in burn center patients is increasing due to the emergence of multidrug-resistant gram-negative bacteria. However, optimal dosing strategies and factors that may contribute to treatment failure are limited. The purpose of this study was to determine factors that may contribute to treatment failure in colistin-treated burn center patients. METHODS: This retrospective, observational study included burn center patients that received ≥48h of intravenous CMS between June 1, 2009 and June 30, 2014. Data was collected utilizing the institution's electronic medical record system. Statistical analysis included demographic, univariable, and multivariable analysis to determine factors that may predict clinical failure of burn center patients requiring intravenous CMS. RESULTS: Eighty-one patients were included in this study, with 55 patients (68%) achieving clinical success. A total daily dose (TDD) of >5mg/kg ideal body weight (IBW) was associated with significantly less clinical failure (odds ratio=0.21; 95% CI, 0.05, 0.91). Additionally, clinical failure was significantly higher in patients with wounds as the primary source of infection, creatinine clearances of 91-120mL/min, and those receiving renal replacement therapy. No difference was observed in nephrotoxicity when comparing TDD >5mg/kg IBW and TDD ≤5mg/kg IBW. CONCLUSIONS: Clinical success was significantly higher with larger intravenous CMS doses in burn center patients. Higher CMS doses were not found to be associated with increased nephrotoxicity within this patient group.
引用
- Wilkinson RE, Hill DM, Hickerson WL, et al. Outcome analysis of colistin-treated burn center patients. Burns. 2017. PMID: 28410932. doi:10.1016/j.burns.2017.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。